Bristol Myers Squibb developed Zeoposia (ozanimod) for use in multiple sclerosis patients. NICE (National Institute for Health and Care Excellence) in Britain released a report detailing its findings on the drug, citing cost concerns. Drugs for use in MS are greatly needed and an ICER (Institute for Clinical and Economic Review) report noted that all but one of 15 drugs would require substantial price decreases to address over-pricing. NICE is collecting feedback and it’s possible the rejection could be overturned.
According to NICE, “the cost-effectiveness estimates for ozanimod compared with other first-line treatments for relapsing–remitting multiple sclerosis were outside what NICE normally considers an acceptable use of NHS resources.” Learn more here.
(Source: Arlene Weintraub, Fierce Pharma, 1/22/21)
